Fusion Antibodies plc (AIM:FAB)

Fusion Antibodies Revenue

In the fiscal year ending March 31, 2026, Fusion Antibodies had annual revenue of 2.11M GBP with 7.38% growth. Fusion Antibodies had revenue of 1.27M in the half year ending March 31, 2026, with 113.78% growth. That makes Fusion Antibodies the 41,617th largest company in the world by revenue and 814th in the United Kingdom.

• Revenue: 2.11M
• Revenue Growth: +7.38%
• P/S Ratio: 3.41
• Revenue / Employee: 78.15K
• Employees: 27
• Market Cap: 7.20M

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• North America and Rest Of World 953.00K 45.2%
• United Kingdom 652.00K 30.9%
• Rest of Europe 505.00K 23.9%

Fiscal year ended Mar 31, 2026 See the full Fusion Antibodies breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	2.11M	145.00K	7.38%
Mar 31, 2025	1.97M	829.00K	72.98%
Mar 31, 2024	1.14M	-1.77M	-60.84%
Mar 31, 2023	2.90M	-1.90M	-39.55%
Mar 31, 2022	4.80M	634.00K	15.22%
Mar 31, 2021	4.17M	270.00K	6.93%
Mar 31, 2020	3.90M	1.71M	78.51%
Mar 31, 2019	2.18M	-508.74K	-18.91%
Mar 31, 2018	2.69M	776.79K	40.59%
Mar 31, 2017	1.91M	432.69K	29.21%
Mar 31, 2016	1.48M	571.97K	62.90%
Mar 31, 2015	909.29K	186.25K	25.76%
Mar 31, 2014	723.05K	318.05K	78.53%
Mar 31, 2013	405.00K	-87.30K	-17.73%
Mar 31, 2011	492.29K	55.35K	12.67%
Mar 31, 2010	436.95K	-24.11K	-5.23%
Mar 31, 2009	461.06K	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Sep 11, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company. Revenue geography data is provided by S&P Global Market Intelligence.

Update frequency:

Semi-annually

Last checked:

Nov 4, 2026

Data Sources Report a data error